Feb 28 2019
Innovation begins when there is a need for something better. The Monarch™ Platform has been named a 2019 Edison Award finalist in the medical/dental category. The annual award competition honors excellence in new product and service development, marketing, human-centered design and innovation.
Since its inception in 1987, the Edison Awards have sought to foster innovation by recognizing the same pioneering spirit and transformative product development methods displayed by Thomas Alva Edison. Edison Award winners represent game-changing products and services, as well as excellence and leadership in innovation around four criteria: Concept, Value, Delivery and Impact.
“We are excited to be considered for such a prestigious award,” said Eric Davidson, Vice President of Sales and Marketing. “At Auris™, we aim to leverage the power of flexible robotics to open up new possibilities in endoscopy – the use of small cameras and tools to enter the body through its natural openings. Our hope is that this innovation can minimize the number of lung cancer deaths that result from not finding advanced cancer earlier. The Monarch Platform is designed to address the limitations of current technology and we intend to deliver on the promise of improving patient care, starting with earlier and more accurate diagnosis of pulmonary nodules.”
Auris Health’s revolutionary Monarch Platform, the first FDA-cleared robotic platform for diagnostic and therapeutic bronchoscopic procedures, is designed with clinician ease-of-use in mind, with a dedicated camera and instrument channel, allowing continuous vision without removal of the camera to pass instruments. The platform’s design centers on a revolutionary, flexible endoscopic technology that promises to fight lung cancer by enabling physicians to diagnose hard-to-reach, small peripheral nodules earlier and with greater precision than ever before. Representing a serious advancement in current minimally invasive techniques, the Monarch Platform enables physicians to access early stage lung cancer without incisions while the cancer can still be treated.
Edison Award finalists are reviewed by a steering company of over 3,000 senior business executives and academics from across the country. Gold, silver and bronze winners, recognized for their excellence in the award’s four criteria, will be presented at the 2019 Edison Awards in New York, NY on April 4, 2019.
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.